Dr. Joseph Kittle, Assistant Professor of Chemistry and Biochemistry at Ohio University, was mentioned in a Columbus Business First article on “Applied Biomolecular Technologies building biotech commercialization engine.”
Dr. Joseph Kittle
Applied Biomolecular Technologies Inc. is owned by three former Battelle biotech researchers and an entrepreneur pursuing a private path to getting research out of academic laboratories and into the marketplace.
One of their newest subsidiaries, Lattice Biotech LLC, is trying to raise $5 million to advance technology it licensed from Nationwide Children’s Hospital to make antibodies that weaken protective films around infectious bacterial colonies. But that’s just one of a half-dozen biotech ventures it’s developing, focused on molecular engineering, DNA and the biochemistry of proteins.
“Anything that involves antibodies is our sweet spot,” CEO Nick Henderson said. “The most unique element we have is a scientific infrastructure within a commercialization lab.”
Henderson was employee No. 5 when he joined the company in January 2012. Now it’s up to 23 employees, more than half doctorate-level researchers in two Columbus labs and another in Athens….
The team then brought on J.D. Kittle, an Ohio University professor and another former Battelle colleague, to form Molecular Technologies Laboratories LLC in Athens, which opened in July 2012 with a paying client. It genetically engineers bacteria to product useful biological materials.
About Molecular Technologies Laboratories LLC
MTL has developed an advanced technology for genetically engineering superior microbial strains and protein products. The current tools are difficult to work with and yield unstable bio production systems resulting in a product development bottleneck. Their engine features a disruptive technology that utilizes a more efficient process to create stable bacterial strains that radically lower process development and production costs. Competing tools rely on plasmid based systems and represent 1980s technology. MTL technology enables enhanced microbial strain development that couples product development to production scale up. MTL also extends its stable protein expression technology to include gene/protein sequence optimization and processing optimization. MTL is part of the Ohio University Innovation Center.
Comments